Hikma Pharmaceuticals (GB:HIK) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Hikma Pharmaceuticals faced significant opposition during their 2024 Annual General Meeting regarding the Rule 9 Waiver for a potential share buyback program. Despite over 20% of shareholders voting against the waiver, the company emphasized the importance of maintaining flexibility to return value through buybacks. Hikma continues to engage with shareholders to address concerns and ensure transparency in its financial strategies.
For further insights into GB:HIK stock, check out TipRanks’ Stock Analysis page.